Subunit influenza vaccination in adults with asthma: effect on clinical state, airway reactivity, and antibody response The Chief Medical Officer recommends an annual influenza vaccination for patients with chronic pulmonary disease including asthma. Some doctors may be reluctant to vaccinate asthmatic patients because of the risk of inducing increased bronchial reactivity' and exacerbating their patients' asthma. Reactions to these vaccines may be due to non-immunogenic impurities, which are not present in the more recently developed subunit vaccines. In subunit vaccines the surface antigens are separated from the virus core by selective solubilisation.2 These vaccines cause fewer side effects when given to normal subjects.3 We therefore studied the effect of one dose of a subunit vaccine on airway reactivity, symptoms, and peak flow rate in patients with chronic stable asthma and measured the antibody response in these patients.
Patients, methods, and results
Fourteen asthmatic patients (12 men and two women) with a mean age of 44 years (range 24-65) were studied. All patients were non-smokers. Eight patients had had asthma since childhood, and 11 were atopic as judged by results of skin prick tests, although none was allergic to eggs. These patients had moderately severe asthma with daily symptoms and a mean forced expiratory volume in one second when stable of 74% of predicted values. All the patients required regular daily treatment with inhaled 2 agonists, and 11 also required regular inhaled corticosteroids. Two patients were taking theophylline, and one was taking cromoglycate.
Baseline spirometry and histamine challenge tests were performed on all patients.4 They were then asked to record their peak expiratory flow rates every morning and evening, complete daily symptom score charts (morning tightness, daytime asthma, cough, and night asthma), and record their use of bronchodilator drugs for one week. After a second set of baseline lung function measurements, histamine challenge tests, and baseline serology had been performed the patients were vaccinated with 0-5 ml of subcutaneous Influvac subunit (Duphar Laboratories Ltd) containing the following: influenza A/Philippines/2/82 (H3N2) 10 ILg HA; influenza A/Brazil/11/78 (HlNl) 10 pg HA; and influenza B/Singapore/22/79 10 pig HA. The lung function measurements and histamine challenge tests were repeated two days and two weeks after vaccination at the same time ofday. Antibody titres were also measured again two weeks after vaccination using complement fixation tests to monitor natural infection and a radial haemolysis test to detect vaccine induced antibodies to viral surface antigens.5
None of the patients experienced any local or systemic side effects after vaccination, and there were no significant changes in symptoms of asthma, use of bronchodilator drugs, or peak expiratory flow rates (Student's t test). There were also no significant changes in lung function measurements and results of histamine challenge tests either during the week before vaccination or two days and two weeks after vaccination (figure). 
Comment
In this study subunit influenza vaccination was well tolerated by a group of patients with moderately severe asthma. Substantial antibody responses were noted in all patients to at least one of the components of the vaccine. Removal of the virus core from the vaccine therefore seems to reduce the local and systemic side effects of vaccination while maintaining the immunogenic properties of the vaccine.
In seven of the asthmatic patients results of skin prick tests to feather antigen were positive, but none of them exFperienced any reactions after vaccination. Since there is no evidence to suggest that a positive result in a skin prick test to a feather antigen is a contraindication to influenza vaccination we believe that this recommendation should be revised.
This study was not intended to determiine whether or not subunit vaccine provides adequate protection against influenza infection in asthmatic patients. Such an investigation would require a large scale study, preferably during an influenza epidemic. We have shown, however, that subunit vaccine is well tolerated by asthmatic patients and is immunogenic. for Egyptian (schistosomal) splenomegaly. In addition, he was found to have iron deficiency anaemia (haemoglobin concentration 11-2 g/l). After nasogastric intubation and fluid replacement (including 1 unit of blood) laparotomy was performed through a paramedian incision. There were some 3 litres of haemorrhagic ascites and a gangrenous segment of jejunum 76 cm long. There was a clear cut line of demarcation between the viable and non-viable bowel but no constriction ring and nothing to suggest previous entrapment of the loop. Thrombosis was observed in the small mesenteric veins draining the affected segment, but the major mesenteric and splenic veins were all patent. The liver and colon seemed normal.
After resection of the gangrenous small bowel with end to end anastomosis the patient recovered and was discharged home 12 days later. Histological examination showed thrombosis of medium sized mesenteric veins and arteries, which contained numerous ova ofS mansoni type. There was coagulative'necrosis of the resected bowel but no evidence of arteritis or any other underlying cause for vascular occlusion.
The pathological lesions of schistosomiasis result from the deposition of a large number oflive ova-in the serosal and submucosal layers of the intestine. Bronchoconstrictor properties of preservatives in ipratropium bromide (Atrovent) nebuliser solution
The original formulation of ipratropium bromide nebuliser solution (Atrovent) caused paradoxical and severe bronchoconstriction in some asthmatic patients. We showed that this response was due to hypotonicity of the original solution,' and as a consequence it was reformulated to render it isotonic. Recently, however, bronchoconstriction after inhalation ofisotonic ipratropium bromide solution has also been reported. As well as containing the active ingredient ipratropium bromide, Atrovent also contains benzalkonium chloride (0-25 g/l) and edetic acid (EDTA) (0-5 g/l). We investigated the role of these additives in causing bronchoconstriction.
Patients, methods and results
Twenty tWO subjects with stable asthma (10 women, 12 men, mean (SEM) age 41 (3) years) whose airways response to isotonic Atrovent nebuliser solution had no>t been determined were studied. All patients initially attended the laboratory to inhale 4 ml isotonic Atrovent followed by measurement of forced expiratory volume in one second (FEy,) for up to 60 minutes. Those in whom the FEV1 fell
